Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer

Tae-Hwe Heo; Joseph Wahler; Nanjoo Suh

doi:10.18632/oncotarget.7102

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer

Tae-Hwe Heo _, Joseph Wahler and Nanjoo Suh

PDF | HTML | How to cite

Oncotarget. 2016; 7:15460-15473. https://doi.org/10.18632/oncotarget.7102

Metrics: PDF 3947 views | HTML 7814 views | ?

Abstract

Tae-Hwe Heo1,2, Joseph Wahler2 and Nanjoo Suh2,3

1 NP512, Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Seoul, Republic of Korea

2 Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA

3 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Correspondence to:

Tae-Hwe Heo, email:

Nanjoo Suh, email:

Keywords: breast cancer, interleukin-6, gp130

Received: October 05, 2015 Accepted: January 23, 2016 Published: January 31, 2016

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine with known multiple functions in immune regulation, inflammation, and oncogenesis. Binding of IL-6 to the IL-6 receptor (IL-6R) induces homodimerization and recruitment of glycoprotein 130 (gp130), which leads to activation of downstream signaling. Emerging evidence suggests that high levels of IL-6 are correlated with poor prognosis in breast cancer patients. IL-6 appears to play a critical role in the growth and metastasis of breast cancer cells, renewal of breast cancer stem cells (BCSCs), and drug resistance of BCSCs, making anti–IL-6/IL-6R/gp130 therapies promising options for the treatment and prevention of breast cancers. However, preclinical and clinical studies of the applications of anti–IL-6/IL-6R/gp130 therapy in breast cancers are limited. In this review, we summarize the structures, preclinical and clinical studies, mechanisms of action of chemical and biological blockers that directly bind to IL-6, IL-6R, or gp130, and the potential clinical applications of these pharmacological agents as breast cancer therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7102

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer

Abstract